I haven't kept up with the story, but are these the Australian results that weren't released last year? If so, it's an interesting issue. Did they change the way it is measured to make it more like the US trials, which are more objective and not performed by the inventor? Either way, it will be interesting to compare them with past results and the US results and to see which diseases are listed.
Ann: ResApp Presentation at ASX Spotlight Investor Conference, page-9
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)